IMMP
IMMUTEP Ltd
NASDAQ · Healthcare · Biotechnology · AU
$3.33
+0.30%Year over year
Reported trailing growth
- Revenue
- +230.1%
- EBITDA
- -30.6%
- EBIT
- +32.3%
- EPS
- -26.8%
- Free cash flow
- +7.6%
- Operating cash flow
- +7.7%
Forward estimates
Based on analyst estimates
- Revenue
- -82.9%
- EBITDA
- +76.1%
- EPS
- +72.1%
Three-year CAGR
- Revenue
- +59.6%
- EBITDA
- -27.4%
- EBIT
- +35.1%
- Net income
- -26.3%
- EPS
- -26.8%
- Free cash flow
- +12.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026